Evidence map›Paper›PMID 33160207›Full record

Trial reportEBioMedicine2020

Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity.

Andrea Padoan, Francesco Bonfante, Matteo Pagliari, Alessio Bortolami, Davide Negrini, Silvia Zuin, Dania Bozzato, Chiara Cosma, Laura Sciacovelli, Mario Plebani

Open access · goldAbstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 3 syntheses or guidelines pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Andrea PadoanDepartment of Medicine-DIMED, Medical School, University of Padova, Italy; Department of Laboratory Medicine, University-Hospital of Padova, Italy.
Francesco BonfanteLaboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy.
Matteo PagliariLaboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy.
Alessio BortolamiLaboratory of Experimental Animal Models, Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy.
Davide NegriniDepartment of Medicine-DIMED, Medical School, University of Padova, Italy.
Silvia ZuinDepartment of Medicine-DIMED, Medical School, University of Padova, Italy.
Dania BozzatoDepartment of Medicine-DIMED, Medical School, University of Padova, Italy; Department of Laboratory Medicine, University-Hospital of Padova, Italy.
Chiara CosmaDepartment of Laboratory Medicine, University-Hospital of Padova, Italy.
Laura SciacovelliDepartment of Laboratory Medicine, University-Hospital of Padova, Italy.
Mario PlebaniDepartment of Medicine-DIMED, Medical School, University of Padova, Italy; Department of Laboratory Medicine, University-Hospital of Padova, Italy. Electronic address: mario.plebani@unipd.it.
University of Padua · ITIstituto Zooprofilattico Sperimentale delle Venezie · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReliable high-throughput serological assays for SARS-CoV-2 antibodies are urgently needed for the effective containment of the COVID-19 pandemic, as it is of crucial importance to understand the strength and duration of immunity after infection, and to make informed decisions concerning the activation or discontinuation of physical distancing restrictions.

methodsIn 184 serum samples from 130 COVID-19 patients and 54 SARS-CoV-2 negative subjects, the analytical and clinical performances of four commercially available chemiluminescent assays (Abbott SARS-Cov-2 IgG, Roche Elecsys anti-SARS-CoV-2, Ortho SARS-CoV-2 total and IgG) and one enzyme-linked immunosorbent assay (Diesse ENZY-WELL SARS-CoV-2 IgG) were evaluated and compared with the neutralization activity achieved using the plaque reduction neutralization test (PRNT).

findingsPrecision results ranged from 0.9% to 11.8% for all assays. Elecsys anti-SARS-CoV-2 demonstrated linearity of results at concentrations within the cut-off value. Overall, sensitivity ranged from 78.5 to 87.7%, and specificity, from 97.6 to 100%. On limiting the analysis to samples collected 12 days after onset of symptoms, the sensitivity of all assays increased, the highest value (95.2%) being obtained with VITRO Anti-SARS-CoV-2 Total and Architect SARS-CoV-2 IgG. The strongest PRNT

interpretationThe results confirmed that all immunoassays had an excellent specificity, whereas sensitivity varied across immunoassays, depending strongly on the time interval between symptoms onset and sample collection. Further studies should be conducted to achieve a stronger correlation between antibody measurement and PRNT

fundingNone.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 Serological TestingSARS-CoV-2AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralAntibodiesClinical performancesImmunoassaysSARS-CoV-2Serology

Identifiers

PMID33160207
PMCPMC7640894
OpenAlexW3097453900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.